South Korea · Healthcare · KRW (Millions) · Annual
Key financials
KRW|Millions
ROE
-8.34%
2025 (actual)
ROA
-4.4%
2025 (actual)
Gross Margin
54.53%
2025 (actual)
Net Margin
-26.14%
2025 (actual)
Total Assets
₩145,008.36M
2025 (actual)
Net Income
-₩6,428.09M
2025 (actual)
Valuation
₩247,219.72M
2026 (forecast)
Stock Price
₩6,880
Historical & projected performance
KRW|Millions
Reported figures and Equlion model projections for the next 5 years.
ROE
+55.1 pt
Company
ROA
-82.3 pt
Company
Gross Margin
-12.8 pt
Company
Sector average
Net Margin
-215.3 pt
Company
Total Assets
-12.8%
Company
Sector average (own scale)
Net Income
-1,552.1%
Company
Sector average (own scale)
Valuation
+160.2%
Company
Sector average
Stock Price
+160.2%
Company
Sector average
Amounts in KRW (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2026. Projections are model estimates, not investment advice.
Want the full financial forecast report for Genome & Company? It covers the balance sheet, income statement, cash flow and Equlion model projections.